# Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC

> **NCT03672305** · EARLY_PHASE1 · UNKNOWN · sponsor: **The Second Hospital of Nanjing Medical University** · enrollment: 50 (estimated)

## Conditions studied

- Primary Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** c-Met/PD-L1 CAR-T cell injection

## Key facts

- **NCT ID:** NCT03672305
- **Lead sponsor:** The Second Hospital of Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-01
- **Primary completion:** 2019-10-30
- **Final completion:** 2019-10-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2018-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03672305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03672305, "Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03672305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*